Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Payor Coverage: Page 4
CMS issues guidance on coverage for COVID-19 tests
By
LabPulse.com staff writers
The move is an effort to mitigate financial barriers Americans may face to receiving COVID-19 testing and health services, CMS said.
April 12, 2020
Waiver allows pathologists to work remotely during pandemic
By
LabPulse.com staff writers
Through a waiver, pathologists have regulatory flexibility in terms of where they work, with temporary relief from the CLIA regulations, which require pathologists to perform diagnostic tests at certified facilities.
March 26, 2020
CAP suspends facility accreditation inspections
By
LabPulse.com staff writers
The U.S. suspension was approved by the U.S. Centers for Medicare and Medicaid Services (CMS) and took effect March 17. It applies to all inspections aside from immediate jeopardy complaint visits and follow-ups, CAP explained to members.
March 17, 2020
CMS starts COVID-19 pricing at $36 per test
By
LabPulse.com staff writers
The release of payment rates complements the agency's release of codes for COVID-19 testing in March and February and will enable healthcare providers and clinical labs to bill for the diagnostic tests. CMS is instructing labs to use Healthcare Common Procedure Coding System (HCPCS) code U0001 for tests developed by the U.S. Centers for Disease Control and Prevention and code U0002 for tests developed by other entities.
March 12, 2020
Blue Cross waives costs for COVID-19 testing
By
LabPulse.com staff writers
Blue Cross said it encourages anyone showing symptoms of COVID-19 to contact their health provider before they visit an office or emergency room. The provider can evaluate their symptoms before determining if diagnostic testing is appropriate.
March 8, 2020
Revival of VALID Act draws mixed response
By
Brian Casey
The issue of diagnostics regulation has emerged as a political lightning rod, with some faulting the Trump administration's response to the outbreak and others blaming what they claim is a history of federal overregulation of clinical labs.
March 8, 2020
CMS adds new code for coronavirus tests
By
LabPulse.com staff writers
The code (U0002) can be used by laboratories to bill for tests for SARS-CoV-2 infection and the respiratory disease caused by the virus, COVID-19, using diagnostics that are not provided by the U.S. Centers for Disease Control and Prevention (CDC). CMS issued the first code, U0001, to track patients tested with the CDC's own diagnostic for the coronavirus.
March 5, 2020
CDC coronavirus test comes to labs | A closer look at payment policy | CRISPR drives diagnostics
By
Emily Hayes
Dear LabPulse Member,
February 10, 2020
CMS delays data reporting for labs
By
LabPulse.com staff writers
Per the Protecting Access to Medicare Act (PAMA) of 2014, labs are required to report a range of data points for clinical diagnostic laboratory tests that are not advanced assays, including Healthcare Common Procedure Coding System (HCPCS) codes, associated private payor rates, and volume data.
January 16, 2020
T2 Biosystems recruits Chembio's John Sperzel as new CEO
By
LabPulse.com staff writers
In the statement about the appointment, T2 noted that during his tenure at Chembio, Sperzel established U.S. and international sales teams that generated significant growth, and the company also made commercial investments in Latin America and Southeast Asia. Sperzel is replacing John McDonough, who will continue to serve as nonexecutive chairman of the board.
January 8, 2020
Congress skips surprise billing, passes LAB Act
By
Emily Hayes
Per the LAB Act data reporting requirements on payments for lab services associated with the Protecting Access to Medicare Act of 2014 (PAMA) will be delayed for one year. Furthermore, an independent study will be commissioned on data collection and rate setting for lab services.
December 22, 2019
Top 10 LabPulse stories for 2019
By
Emily Hayes
In the No. 1 position was a story by contributing writer Joseph Constance that ran in November about how to manage the transition to lab automation. It's no surprise that lab managers are turning to automation to improve efficiency and generate new revenue as a means of compensating for declining reimbursement. Similarly, artificial intelligence promises gains in efficiency through the automation of some processes of clinical evaluation, in theory allowing more time for human analysis where it is really needed. It's early days yet for AI, and we will be following the trials and tribulations.
December 22, 2019
Previous Page
Page 4 of 5
Next Page